Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk by Petenkaya, A. et al.
Abstract. Background: A T-to-G polymorphism (SNP309) at
the promoter region of MDM2 has been recently reported to
extend the Sp1 binding site that positively regulates the MDM2
transcription level and consequently, its expression level. MDM2
is the negative regulator of p53 tumor suppressor protein and
elevated levels of MDM2 hamper the stress response driven by
the p53 pathway. Whether MDM2-SNP309 was associated with
breast cancer as a predisposing factor was investigated. Patients
and Methods: A case-control study of 223 females diagnosed
with breast cancer and 149 female controls sampled from the
Turkish population was carried out and the T/G MDM2-
SNP309 genotype of participants was determined. Results:
There was no significant association of the G/G or G/T
genotypes with breast cancer risk (odds ratio (OR) 1.14, 95%
confidence interval (CI) 0.59-2.22, and OR 1.20, 95% CI 0.67-
2.12, respectively). Stratification of the data for onset age or for
menopausal status at the time of diagnosis also revealed no
association for either group.
It has been well established that the p53 tumor suppressor
gene, a principal mediator of multiple functions, plays a
vital role in the positive regulation of apoptosis, cell cycle
arrest and cellular senescence in response to DNA damage
or various types of stress (1). 
Bond et al. reported a T-to-G polymorphism at nucleotide
309 in the promoter region of MDM2 that increases the
MDM2 transcription levels due to formation of an improved
binding site for the transcription activator Sp1 (2). MDM2 is
an oncoprotein that negatively regulates the stability of p53
through binding at the p53 transcriptional activation domain
and promoting its degradation through ubiquitination. MDM2
is also overexpressed in many human tumors, including breast
cancer (2, 3) raising the possibility that the G allele of SNP309
could be a strong cancer-predisposing allele. 
Whether the G allele of SNP309 acted as a breast cancer
predisposition factor was investigated in a case-control study
among Turkish women, taking into account the menopausal
status and age of onset of the disease.
Patients and Methods
Study participants. Our case group consisted of 223 females who
were diagnosed with breast cancer yet with no apparent family
history of breast cancer (ductal breast carcinoma, mean age: 51,
standard deviation: 13.2, age range: 20-80). Histopathology of the
tumor and age at diagnosis were obtained through medical records.
The age-matched control group consisted of 149 apparently healthy
Turkish women with no history of cancer (mean age: 47, standard
deviation: 15.6, age range: 15-83). A standardized questionnaire
including information on age, menopausal status, family history of
breast cancer, smoking history, and height and weight was
completed for each individual at the Ankara Numune Research
and Teaching Hospital, Turkey. Informed consent was obtained
from all participants. 
Genotyping. Genomic DNA was isolated from 200 Ìl peripheral blood
using a DNA mini kit (Macherey-Nagel, Germany) according to the
manufacturer’s instructions. PCR and RFLP analysis were used to
genotype the T/G MDM2-SNP309 polymorphism. PCR primers used
were 5’-GCTTTGCGGAGGTT TTGTT-3’ (sense) and 5’-
CGGAACGTGTCTGAACTTGA-3’ (antisense). PCR was done
under standard conditions using 20 ng of genomic DNA and an
annealing temperature of 55ÆC. The resulting 304 bp PCR product
was digested by sA1I. The fragments resolved on a 3% agarose gel
containing ethidium bromide gave three distinct patterns for SNP309:
T/T, G/T and G/G genotypes. The wild-type T allele produced 193
and 111 bp fragments, whereas G/T alleles produced one more
restriction site resulting in 193, 147, 111 and 46 bp fragments.
Statistical analysis. The genotype frequencies were compared using
Pearson’s Chi-squared and Fisher’s exact test. Odds ratios (OR)
and 95% confidence intervals (CI) were also calculated using 2x2
contingency tables. All the calculations were conducted with R
2.2.1 statistical computing software (4). 
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Results and Discussion
Allele and genotype frequencies of the MDM2-SNP309
polymorphisms for the breast cancer patients and control
groups are summarized in Table I. Neither the patient nor
the control groups showed significant deviation from the
Hardy-Weinberg Equilibrium (control group p=0.5,
patient group p=0.14). There was no significant
association of the G/G or G/T genotypes with breast
cancer (OR 1.14, 95% CI 0.59-2.22 and OR 1.20, 95% CI
0.67-2.12, respectively, Table I). 
In a recent study by Bond et al. (5), it was indicated that
female breast cancer patients, who were below the average
age of menopause, had a higher frequency of G/G genotype
for SNP309 and were affected differently by estrogen
signalling. However, stratification of the data according to
age and menopausal status in this Turkish population did
not change the results (Table II). There was no significant
difference between the allelic frequencies of the control
group (n=298 alleles) and those of the patient group
(n=446 alleles) (¯2=0.9, df=1, p=0.34). No evidence of a
higher G/G distribution (25% of 82 pre-menopausal
patients vs. 25% of 123 post-menopausal patients) was
found among the breast cancer patients who were at their
pre-menopausal period at the time of diagnosis. 
Several studies have demonstrated that SNP309
accelerates tumor formation in patients with hereditary Li-
Fraumeni Syndrome (2) and in various cancer types
including colorectal cancer (6), bladder cancer (7) and non-
small cell lung cancer (8). In contrast to these findings,
other studies have shown that the T309-G polymorphism
was not associated with ovarian and sporadic breast cancer
(10) or with hereditary breast cancer (10). 
In a study by Boersma et al. (11), the unstratified data
and the stratified data by race did not reveal any association
of SNP309 with breast cancer risk. Another study by Ma et
al., reported that this polymorphism did not play any
verifiable role in breast cancer development in the Chinese
population (12). 
Conclusion
These results together with our own findings suggest that
although the role of the MDM2-SNP309 polymorphism
reveals discordant results among different types of cancer in
various ethnic groups, there seems to be no association
between the G allele and breast cancer risk among the
different ethnic groups so far examined. Additionally, no
association was found between the risk-defining G allele
and menopausal status or age of onset of the disease. 
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